A detailed history of Rafferty Asset Management, LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 12,896 shares of ARVN stock, worth $232,128. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,896
Previous 13,078 1.39%
Holding current value
$232,128
Previous $348,000 8.91%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$23.66 - $32.73 $4,306 - $5,956
-182 Reduced 1.39%
12,896 $317,000
Q2 2024

Aug 13, 2024

BUY
$24.46 - $40.4 $122,128 - $201,717
4,993 Added 61.76%
13,078 $348,000
Q1 2024

May 13, 2024

BUY
$36.38 - $52.31 $294,132 - $422,926
8,085 New
8,085 $333,000
Q3 2022

Nov 14, 2022

SELL
$41.87 - $57.99 $41,702 - $57,758
-996 Reduced 16.86%
4,911 $218,000
Q2 2022

Aug 12, 2022

BUY
$36.01 - $74.24 $32,769 - $67,558
910 Added 18.21%
5,907 $249,000
Q1 2022

May 13, 2022

SELL
$60.27 - $81.57 $149,770 - $202,701
-2,485 Reduced 33.21%
4,997 $336,000
Q4 2021

Feb 10, 2022

BUY
$65.85 - $96.21 $36,546 - $53,396
555 Added 8.01%
7,482 $615,000
Q3 2021

Nov 10, 2021

BUY
$73.2 - $107.87 $246,903 - $363,845
3,373 Added 94.91%
6,927 $569,000
Q2 2021

Aug 10, 2021

SELL
$60.45 - $84.26 $86,020 - $119,901
-1,423 Reduced 28.59%
3,554 $274,000
Q1 2021

May 10, 2021

SELL
$58.19 - $91.37 $13,150 - $20,649
-226 Reduced 4.34%
4,977 $329,000
Q4 2020

Feb 10, 2021

BUY
$20.19 - $84.93 $105,048 - $441,890
5,203 New
5,203 $442,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $958M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.